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Abstract: A cancer dogma states that inactivation of 
oncogene(s) can cause cancer remission, implying that 
oncogenes are the Achilles’ heel of cancers. This cur-
rent model of cancer has kept oncogenes firmly in focus 
as therapeutic targets and is in agreement with the fact 
that in human cancers all cancerous cells, with inde-
pendence of the cellular heterogeneity existing within 
the tumour, carry the same oncogenic genetic lesions. 
However, recent studies of the interactions between an 
oncogene and its target cell have shown that oncogenes 
contribute to cancer development via developmental 
reprogramming of the epigenome within the target cell. 
These results provide the first evidence that carcinogen-
esis can be initiated by epigenetic stem cell reprogram-
ming, and uncover a new role for oncogenes in the origin 
of cancer. Here we analyse these evidences and discuss 
how this vision offers new avenues for developing novel 
anti-cancer interventions.
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Introduction
Since the discovery that human cancers contain activated 
oncogenes, many efforts have been made to elucidate the 
causal role that these oncogenes play in cancer develop-
ment. These previous works have shown that oncogene 
expression is not only required for initiation of cancer 
but also for the maintenance of the disease and have 
kept oncogenes firmly in focus as therapeutic targets. In 
mouse models where oncogene expression is driven by 
tissue-specific promoters, tumours arise at high frequen-
cies, but disappear again when the inducing stimulus is 
switched off (Chin et al., 1999; Huettner et al., 2000; Boxer 
et al., 2004), suggesting that oncogenes are the Achilles’ 
heel of cancers (Weinstein, 2002). Overall, these obser-
vations define a homogenous role for oncogenes within 
cancer cells (Figure 1A), as brief inactivation of the single 
tumour-inducing oncogene can cause remission in these 
model systems. These observations are consistent with a 
role for oncogenes in regulating tumour mass formation 
in a similar way to the control of cell-fate determination 
as a function of lineage-specific factors (Vicente-Duenas 
et al., 2013, 2014).
This current model of cancer is in agreement with the 
fact that in human cancers, all cancerous cells carry the 
same oncogenic genetic lesions. However, it is also a very 
well-known fact that cancers are composed of heterogene-
ous cell types (Hanahan and Weinberg, 2011), suggesting 
that, in the control of oncogenesis, the nature of the target 
cells suffering the effects of oncogenic activity might play 
an important role. In fact, therapy based on the current 
working model of cancer fails to eradicate tumours in 
humans, as is well illustrated by the BCR–ABL kinase 
inhibitors such as imatinib/STI571, which can target the 
differentiated tumour cells of chronic myeloid leukaemia 
(CML) but fail to eradicate the BCR-ABL-expressing leu-
kaemia stem cells (Chomel et  al., 2011; Chu et  al., 2011; 
Corbin et  al., 2011; Hamilton et  al., 2012; Kumari et  al., 
2012). On the contrary, these observations are compatible 
with the cancer stem cell (CSC) theory of cancer that sug-
gests that tumours are hierarchically organized tissues 
*Corresponding authors: Carolina Vicente-Dueñas and Isidro 
Sánchez-García, Experimental Therapeutics and Translational 
Oncology Program, Instituto de Biología Molecular y Celular del 
Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno 
s/n, E-37007 Salamanca, Spain; and Institute of Biomedical 
Research of Salamanca (IBSAL), 37007 Salamanca, Spain,  
e-mail: cvd@usal.es, isg@usal.es 
Alberto Martín-Lorenzo, Inés Gonzalez-Herrero, Guillermo 
Rodríguez-Hernández and Idoia García-Ramírez: Experimental 
Therapeutics and Translational Oncology Program, Instituto de 
Biología Molecular y Celular del Cáncer, CSIC/Universidad de 
Salamanca, Campus M. de Unamuno s/n, E-37007 Salamanca, 
Spain; and Institute of Biomedical Research of Salamanca (IBSAL), 
37007 Salamanca, Spain
Brought to you by | CSIC - Unidad Coordinacion Bibliotecas
Authenticated
Download Date | 7/14/16 12:36 PM
1316      A. Martín-Lorenzo et al.: Early epigenetic cancer decisions
(Reya et  al., 2001; Pardal et  al., 2003; Perez-Losada and 
Balmain, 2003). If that was indeed the case, then cancer 
could be created and maintained similarly to any other 
normal stem cell-driven tissue, like the hematopoietic 
system. In a normal stem cell-driven tissue, genetic pro-
gramming of stem cells is all that is required to (re)con-
stitute all differentiated cells forming the tissue, and the 
genetic information responsible for the stem cell program-
ming does not need to be anymore present within the dif-
ferentiated cells that form the tissue, implying a different 
function for oncogenes within CSCs. Thus, we reasoned 
that a similar organization could be underlying cancer 
formation (Vicente-Duenas et al., 2013, 2014). In order to 
initially address this biological question, we have used 
oncogenic lesions of different types linked to specific 
hematopoietic cancers and proved that they can re-pro-
gramme target stem cells through epigenetic changes, into 
a differentiation state from which tumour cells with differ-
ent properties emerge heterogeneously (Perez-Caro et al., 
2009; Vicente-Duenas et  al., 2012a,c, Romero-Camarero 
et al., 2013).
Limiting oncogene expression to 
stem cells induces cancer in mice
A major barrier for the understanding of the contribution 
that CSCs make to the development and maintenance of 
cancer and their suitability as a target was the lack of a 
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Figure 1 Cellular architecture, drivers and development in cancer.
(A) Current working model for the development of cancer in humans. In the current view of the initiation and progression of cancer, an initi-
ating hit is required to immortalize a target cell. Such cells are then destined to acquire additional genetics hits over time. The acquisition 
of additional hits further deregulates the behaviour of the tumour cells, thus leading to a subclonal genetic heterogeneity within tumour 
cells. Specific subclones of tumour cells may contribute to the initiation, treatment resistance or relapse. (B) The tumour stem cell repro-
gramming model. In human cancer and in most animal models of cancer, the oncogenic alterations are expressed in all the cellular types 
that compose the tumoural tissue, from the target cell to the terminal differentiated tumour cells. In our model, carcinogenesis can be initi-
ated by epigenetic stem cell reprogramming, uncovering a new role for oncogenes in the origin of cancer: the expression of the oncogene 
is restricted to the stem/progenitor compartment, but this restricted expression pattern is nevertheless capable of generating a full-blown 
cancer with all its differentiated cellular components. The demonstration that cancer development can be established in mice by express-
ing the oncogene only in stem/progenitor cells implies that the oncogene can impose an epigenetic regulatory state in these stem cells 
that somehow persists during hematopoiesis. These (epi)genetic changes would not interfere with normal hematopoietic development, but 
become active in the process of terminal differentiation, leading to the appearance of specific tumour differentiated cells. (C) Is epigenetic 
tumour stem cell reprogramming the driver of cancer? The key question emerging from these findings is how a cell can escape the normal 
regulatory mechanisms governing epigenetic modifications such that oncogenic gene-expression patterns can persist, without having DNA-
sequence mutation. It will be challenging to test whether epigenetic modifications (epigenetic tumoural stem cell reprogramming) without 
gene mutations can indeed drive cancer development.
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system to limit oncogene expression to the CSC compart-
ment. To elucidate whether cancer is a stem cell-driven 
tissue, we used the Sca1 locus control region to limit 
oncogene expression to the stem cell compartment in 
a transgenic mouse setting (Perez-Caro et  al., 2009). We 
have initially focused on the effects of the BCR-ABLp210 
oncogene, linked to CML in humans (Koeffler and Golde, 
1981a,b; Melo and Barnes, 2007). CML is widely accepted 
to be a stem-cell disorder where the specific BCR-ABL 
inhibitor STI571 is able to eliminate the BCR-ABL-express-
ing differentiated cells that constitute the bulk of the 
tumour, but it cannot eliminate BCR-ABL-expressing CSCs 
(Chomel et al., 2011; Chu et al., 2011; Corbin et al., 2011; 
Hamilton et al., 2012; Kumari et al., 2012).
When the expression of BCR-ABL is restricted to the 
Sca1+ cells in mice, these Sca1-BCR-ABLp210 mice fully 
develop CML. In these Sca1-BCR-ABLp210 mice, although 
initiation takes place within the stem cell/progenitor pop-
ulation, the oncogene is switched off in the tumour differ-
entiated cells which constitute the bulk of the tumour. In 
the paper by Perez-Caro et al. (2009), quantitative RT-PCR 
analysis of BCR-ABL transcripts was used to define pat-
terns of BCR-ABL gene expression in pure populations of 
hematopoietic cells. Overall, BCR-ABL is not expressed in 
lineage-positive hematopoietic progenitors, but it could be 
that BCR-ABL target genes could continue to be expressed 
in the absence of BCR-ABL. These genes could be targets 
of a ‘hit and run’ mode of action in which BCR-ABL turns 
genes on in stem cells but is not required for maintaining 
their expression at later stages of development. However, 
neither BCR-ABL protein nor downstream signalling was 
detected in Sca1-Lin+ cells of Sca1-BCR-ABLp210 mice. The 
data support the hypothesis that BCR-ABL downstream 
targets are switched off after the silencing of BCR-ABL. 
It might appear then counter-intuitive and surprising 
that cancers develop efficiently in these mice as in actual 
human cancers all cancerous cells carry the oncogenic 
genetic lesions, not only the CSCs (Figure 1A). Neverthe-
less, CML arises in these mice indicating that silencing 
of BCR-ABL is not critical for generation of differentiated 
tumour cells and suggesting a tumour stem cell repro-
gramming role for BCR-ABL in regulating cancer forma-
tion (Figure 1B).
To determine whether the continuous presence of 
BCR-ABL is necessary for the maintenance of CSCs we 
treated diseased Sca1-BCR-ABLp210 mice with the specific 
BCR-ABL inhibitor STI571 and we found that the course of 
the CML disease was not modified upon treatment. These 
observations demonstrate that blocking BCR-ABL function 
(or at least abolishing its tyrosine-kinase activity) is not 
efficient in eliminating the CSCs, indicating that mouse 
CSC are not oncogene addicted. These findings were later 
corroborated in human patients by showing that human 
CSC are not oncogene addicted either (Chomel et al., 2011; 
Chu et al., 2011; Corbin et al., 2011; Hamilton et al., 2012; 
Kumari et  al., 2012). Overall, these observations are in 
agreement with the development of CML following our 
tumour stem cell reprogramming model (Figure 1B).
But because we wanted to address the question of 
whether CSCs are required continuously for maintenance 
of the CML disease, we used a model in which Sca1+, 
BCR-ABL-expressing cells are deleted in the presence of 
gancyclovir. After elimination of the CSC, we were able 
to eradicate the whole tumour (Perez-Caro et  al., 2009). 
These observations formally prove that CSCs are required 
continuously for maintenance of the CML disease. 
However, abolishing BCR-ABL function is not critical for 
the generation of differentiated tumour cells. In our view, 
this constitutes the most convincing evidence to date that 
these cancers arise and are driven by a cell-fate change 
within the stem cells, and that this population is the ulti-
mate target for cancer therapy. In total, the data suggest a 
tumour stem cell reprogramming role for BCR-ABL in regu-
lating cancer formation.
Considering these evidences, and although human 
CML is a paradigmatic stem-cell driven cancer, we rea-
soned that a similar experimental approach to the one 
we used with BCR-ABL could also allow us to reproduce 
in the mouse the genotype-phenotype correlation (spe-
cific oncogene-specific tumour) found in other types of 
human cancers. The most challenging systems in which 
to test this hypothesis are those tumours whose main 
constituent cell type is a mature differentiated cell, such 
as multiple myeloma (MM) or mature B-cell lymphoma. 
In recent reports we have showed that MM (by using 
the MafB oncogene) and B-cell lymphoma (by using 
the MALT1 oncogene) phenotypes and biology can be 
faithfully recapitulated in mice in which specific onco-
gene ectopic expression is limited to stem cell antigen 1 
(Sca1)+ cells, implicating for the first time stem cells in 
the pathogenesis of MM and B-cell lymphoma. Of course, 
the demonstration that MM and B-cell lymphoma devel-
opment can be established in mice by limiting onco-
gene expression to Sca1+ cells implies that abolishing 
oncogene function does not interfere with the differ-
entiated tumour cell formation, and suggest that the 
oncogene imposes a gene regulatory state in stem cells 
that somehow persists during hematopoiesis and which 
imposes a tumour phenotype reflective of the usual MM 
and B-cell lymphoma (Vicente-Duenas et al., 2012a,b,c). 
Therefore, we hypothesize that the cancer-initiating 
oncogenes mediate tumourigenesis through epigenetic 
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modification of target genes that remain in this modified 
state in the mature tumour even in the absence of the 
oncogene in agreement with an epigenetic tumour stem 
cell reprogramming model for oncogenes in regulating 
cancer formation (Figure 1B).
Epigenetic tumour stem cell repro-
gramming: how does an oncogene 
program stem cells to make a 
cancer?
In human pathologies and in most animals models of 
cancer, the oncogenic alteration(s) is(are) present in all the 
cellular types that compose the tumoural tissue, from the 
CSCs to the more differentiated types (Figure 1A). In our 
stem cell-driven cancer model, the expression of the onco-
genic alteration is restricted to the progenitor compartment 
but is nevertheless capable of generating a full-blown 
tumour with all its differentiated cellular components, 
showing a tumour stem cell reprogramming for (some) 
oncogenes in regulating cancer formation (Figure 1B). Of 
course, this model implies that the oncogenic activity in 
the CSC compartment causes epigenetic latent altera-
tions that are responsible for the later appearance of the 
tumoural phenotype (Vicente-Duenas et al., 2013).
In order to gain even more insight into the mecha-
nism by which oncogene can induce the reprogramming 
of stem cells into tumour differentiated cells, we have 
generated in vivo genome-scale maps of DNA methyla-
tion from both stem cells and mature B-cells from Sca1-
MafB mice (Vicente-Duenas et al., 2012c). We found that 
a substantial number of CpG islands and promoters are 
specifically hypermethylated or hypomethylated in the 
stem cells of Sca1-MafB mice, setting a pattern inher-
ited throughout B-cell development. Thus, the results 
presented in our study demonstrate a novel molecular 
mechanism involved in tumour initiation, by showing 
that stem-progenitor cells can be epigenetically repro-
grammed to give rise to terminally differentiated tumour 
plasma cells by MafB (Vicente-Duenas et al., 2012c). To 
our knowledge, these results represent the most convinc-
ing evidence to date that cancer development can arise 
and be driven by a tumour cell-fate change within the 
stem cells. The key question emerging from these find-
ings is how a cell can escape the normal regulatory mech-
anisms governing epigenetic modifications such that 
oncogenic gene-expression patterns can persist, without 
having DNA-sequence mutation. It will be challenging 
to test whether epigenetic modifications (epigenetic 
tumoural stem cell reprogramming) without gene muta-
tions can indeed drive cancer development (Figure 1C). 
However, the clinical implications of such oncogenic 
routes would be far reaching.
This tumoural epigenetic reprogramming is concep-
tually different from the “epigenetic progenitor” model 
of cancer, proposing that cancer formation involves a 
general, non-targeted epigenetic disruption at the level of 
progenitors cells, followed by an initiating mutation and 
then by genetic and epigenetic plasticity. However, in both 
contexts, epigenetic alterations in cancer serve as potent 
surrogates for genetic mutations and are driving forces of 
the initial tumoural development (Feinberg et  al., 2006; 
Iacobuzio-Donahue, 2009).
Tumour suppressors can act as 
barriers for epigenetic tumoural 
stem cell reprogramming
In analogy to what happens in reprogramming to pluripo-
tency (Zhao et al., 2008; Banito et al., 2009; Hong et al., 
2009; Kawamura et  al., 2009; Krizhanovsky and Lowe, 
2009; Li et  al., 2009; Marion et  al., 2009; Utikal et  al., 
2009), the efficiency of the oncogene-induced tumoural 
reprogramming of normal HS/P-Cs to terminally differen-
tiated malignant cells is enhanced by p53 deficiency, at 
least in the cases of BCR-ABL (CML), Malt1 (MALT B-cell 
lymphoma) and MafB (MM) (Velasco-Hernandez et  al., 
2012; Vicente-Duenas et al., 2012a,b). These results suggest 
that the absence of the tumour suppressor does not have 
an instructive role in the genesis of tumour cells, but just a 
permissive one, preventing cells with damage from being 
successfully terminally reprogrammed. In addition, this 
further supports the interpretation that the driving force 
of the tumoural reprogramming process is the oncogene 
itself, and that it is just the need of maintaining genetic 
integrity that prevents the reprogrammed cells with any 
kind of damage to progress along the newly programmed 
malignant pathway (just like in iPSCs generation). Along 
these lines, transient restoration of p53 slows down CML 
disease progression and significantly extends the sur-
vival of leukemic animals (Velasco-Hernandez et  al., 
2012), being the mechanism responsible for this effect 
the p53-mediated apoptotic death of primitive leukaemia 
cells, suggesting that reestablishing p53 function may be a 
therapeutic strategy for the eradication of leukemic stem 
cells and to prevent disease progression.
Brought to you by | CSIC - Unidad Coordinacion Bibliotecas
Authenticated
Download Date | 7/14/16 12:36 PM
A. Martín-Lorenzo et al.: Early epigenetic cancer decisions      1319
Conclusions and future directions
Despite a better understanding of the biology of tumour 
cells, the treatment of most cancers has not significantly 
changed for the past four decades and the decreasing 
mortality has been mostly the result of early detection 
and prevention rather than the consequence of effective 
therapeutics (Etzioni et  al., 2003; Chabner et  al., 2005; 
Huff et  al., 2006). Thus, the cells and genetic lesions 
responsible for maintaining the disease remain an 
intriguing and exciting topic of research, as these cells 
have been posited to be responsible for resistance to con-
ventional therapies, recurrence, and metastasis (Reya 
et al., 2001).
We have shown that cancer growth and elimination 
was achieved by targeting oncogene expression to the 
CSCs only (Perez-Caro et  al., 2009). Thus, if the growth 
potential of a cancer depends on CSCs and on oncogenes 
that can function in an epigenetic tumoural stem cell 
reprogramming manner, it seems important to know how 
to eradicate these cells and/or inactivate the epigenetic 
tumoural stem cell reprogramming mechanism. Similarly, 
assessing the ability of any candidate therapy to destroy 
these cells would seem crucial to predicting its efficacy 
(Vicente-Duenas et al., 2013, 2014).
But perhaps the most crucial question of all is 
whether epigenetic tumoural stem cell reprogramming 
regulation mechanisms can be found in other cancer 
types, especially tumours of epithelial origin, which rep-
resent the bulk of human cancers. Importantly, a small 
subset of Sca1-BCR-ABLp210 mice develops additional 
solid tumours. Considering that Sca1 has been identified 
as an almost universal stem cell marker in many differ-
ent tissues, these data suggest that epigenetic tumoural 
stem cell reprogramming as a driver of cancer is not spe-
cific to only hematopietic tissues, but rather represents a 
broader mechanism for that can be applied to solid-organ 
cancers.
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